Thyroid Diseases, Metformin and the AMP Kinase Pathway
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkiye Klinikleri
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
An increase in the adenosine monophosphate (AMP)/adenosine triphosphate ratio activates AMP-activated protein kinase (AMPK), leading to inhibition of the mammalian target of rapamycin signaling pathway that is associated with autophagy, mitochondriogenesis, glucose uptake, mRNA stabilization, and cell cycle regulation. Metformin activates AMPK and inhibits mitochondria! oxidative phosphorylation. Currently, there is an increasing interest in investigating the effects of metformin on thyroid diseases. Recent data show an association between metformin treatment and lower incidence of thyroid cancer, better survival of patients with thyroid cancer, and lower thyroid volume and nodule size. Insulin-like growth factor receptor and AKT pathways are the AMPK-independent mechanisms through which metformin acts on thyroid diseases. Although metformin has a promising role in adjuvant therapy for thyroid cancers, well-designed prospective trials are required before reaching a final decision.
Açıklama
Anahtar Kelimeler
Thyroid diseases, AMP-activated protein kinase pathway, Activated Protein-Kinase, Signaling Pathway, Growth, Volume, Cells, Tsh
Kaynak
Turkish Journal Of Endocrinology And Metabolism
WoS Q Değeri
N/A
Scopus Q Değeri
Q4
Cilt
25
Sayı
4
